Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, announced the closing of an underwritten public offering that raised approximately $10 million in gross proceeds. The financing, combined with existing cash and a recent $1.5 million investment from Board Chair Michael Hoffman, is expected to extend the company’s cash runway through the second quarter of 2027. This funding will support operations through a key six-month symptomatic data readout from its Phase 3 Alzheimer’s trial and the anticipated New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), while advancing ongoing clinical studies and regulatory preparations.
The company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Phase 3 Alzheimer’s trial is designed to evaluate buntanetap’s ability to improve symptoms and potentially modify the disease course.
The closing of this offering marks a critical milestone for Annovis as it approaches pivotal regulatory and clinical milestones. The company’s ability to secure funding through 2027 provides a clear path to generating late-stage clinical data and preparing for potential market approval. Investors and analysts will be closely watching the six-month symptomatic data readout, which could validate buntanetap’s efficacy and safety profile. A positive outcome would significantly de-risk the program and support the NDA submission, potentially bringing a new treatment option to patients with neurodegenerative diseases.
Annovis Bio, headquartered in Malvern, Pennsylvania, continues to advance its pipeline with a focus on addressing the unmet medical needs in Alzheimer’s and Parkinson’s diseases. The company’s approach targets multiple toxic proteins implicated in neurodegeneration, offering a differentiated mechanism compared to existing therapies. For more information about Annovis and its programs, visit www.annovisbio.com.
The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS. This financing underscores the confidence of investors in Annovis’s strategy and the potential of buntanetap to address critical gaps in neurodegenerative disease treatment.
